2024
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
Epperla N, Huang Y, Cashen A, Vaughn J, Hanel W, Badar T, Barta S, Caimi P, Sethi T, Reddy N, Karmali R, Bello C, Chavez J, Kothari S, Hernandez-Ilizaliturri F, Svoboda J, Lansigan F, Glenn M, Cohen J, Sorge C, Christian B, Herrera A, Hamadani M, Costa L, Xavier A. Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation. Blood Advances 2024, 8: 5458-5466. PMID: 39213424, DOI: 10.1182/bloodadvances.2024013743.Peer-Reviewed Original ResearchPrimary treatment failureAuto-HCTStable diseaseHodgkin lymphomaPartial responseCumulative incidence of non-relapse mortalityIncidence of non-relapse mortalityAssociated with inferior PFSEfficacy of auto-HCTAssociated with inferior OSAutologous hematopoietic cell transplantationEvaluation of prognostic factorsClassical Hodgkin lymphomaNon-relapse mortalityMulticenter retrospective cohortHigh-risk diseaseHematopoietic cell transplantationLong-term efficacyPatterns of failureUS medical centersProgression of diseaseInferior PFSMedian PFSInferior OSComplete responseReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3Lymphoma
2016
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic Advances In Hematology 2016, 8: 13-20. PMID: 28042455, PMCID: PMC5167078, DOI: 10.1177/2040620716676256.Peer-Reviewed Original ResearchProgression-free survivalNodular sclerosis Hodgkin lymphomaSyncytial variantOverall survivalHodgkin's lymphomaSV patientsComplete responseSV groupShorter progression-free survivalMedian overall survivalOutcomes of patientsPoor-risk groupLower CR rateInstitutional review board approvalKaplan-Meier methodSmall case seriesLog-rank testClassical HL patientsReview board approvalAdvanced diseaseInduction regimenAdult patientsClinical characteristicsHL patientsAggressive course
2015
Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in Outcome of Patients with Syncytial Variant Hodgkin Lymphoma (HL) Compared with Typical Nodular Sclerosis HL. Blood 2015, 126: 1441. DOI: 10.1182/blood.v126.23.1441.1441.Peer-Reviewed Original ResearchNodular sclerosis Hodgkin lymphomaProgression-free survivalOutcomes of patientsAdvanced stage diseaseOverall survivalComplete responseHodgkin's lymphomaB symptomsStage diseaseSV groupAchievement of CRInferior progression-free survivalMedian progression-free survivalHodgkin/Reed-Sternberg cellsInstitutional IRB approvalMedian overall survivalStandard ABVD chemotherapyStandard salvage regimensHigh-dose therapyKaplan-Meier methodOnly independent predictorStem cell transplantStage of diseaseCompletion of treatmentNew immunomodulatory agents